Anti-PD-1 Mouse Monoclonal J110

Quick Details (View All)

CAS No.	n/a	Place of Origin	USA
Purity	>95%	Classification	Specific Reagents
Brand Name	Clonegene	Model Number	CG0110
Application	ELISA, WB, IHC, FFPE, IHC	Packaging	100 ug/unit
Dilution Buffer	1%BSA/PBS	Form	LIquid
Isotype	mouse IgG1	Activity	Neutralization of PD1/PDL1 interaction
Conjugation	Non-conjugated	Concentration	1mg/ml
Specificity	human , mouse PD1	Clone	J110

Product Details

Product Description

Programmed cell death protein 1, also known as PD-1 and CD279 (cluster of differentiation 279), is a protein that in humans is encoded by the PDCD1 gene. PD-1 is a cell surface receptor that belongs to the immunoglobulin superfamily and is expressed on T cells and pro-B cells. PD-1 binds two ligands, PD-L1 and PD-L2.

PD-1, functioning as an immune checkpoint, plays an important role in down regulating the immune system by preventing the activation of T-cells, which in turn reduces autoimmunity and promotes self-tolerance. The inhibitory effect of PD-1 is accomplished through a dual mechanism of promoting apoptosis (programmed cell death) in antigen specific T-cells in lymph nodes while simultaneously reducing apoptosis in regulatory T cells (suppressor T cells).

A new class of drugs that block PD-1, the PD-1 inhibitors, activate the immune system to attack tumors and are therefore used to treat cancer.

CG0110 is an excellent reagent to investigate the biology of PD-L1

REFERENCES

Yamane, H., et al. (2015). “Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines.” Am J Cancer Res 5(4): 1553-1557. PubMed

"Programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) play a major role in suppressing the immune system during the formation of the PD-1/PD-L1 pathway, which transmits an inhibitory signal to reduce T cell activity. PD-L1 is often expressed in various malignant tumors. In contrast, PD-1 is generally observed in activated lymphocytes and myeloid-derived dendritic cells. Of the malignant cells, only Jurkat cells under special conditions and angioimmunoblastic T-cell lymphoma tissue cells express PD-1 on their surface. METHODS: To clarify whether the PD-1/PD-L1 pathway participates in the immunotolerance of small-cell lung cancer (SCLC) cells, we examined the expressions of PD-1 and PD-L1 on the cell surface of SCLC cell lines using flow cytometry and reverse transcription polymerase chain reaction. RESULTS: Among the four SCLC cell lines examined, only SBC-3 expressed both PD-1 and PD-L1. CONCLUSIONS: We demonstrated that both PD-1 and PD-L1 molecules were co-expressed on the surface of SCLC cells. Although the biological implications of this remain unclear, we speculate that PD-1 and its ligand on the SCLC cells may participate in the growth inhibition of tumor cells as reported in cytotoxic T cells"

Limitation

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Isotype

IgG1

Clonality

Mouse Monoclonal J110

Concentration

100 µl of a 1.0 mg/ml preparation

Storage Instructions

Heat stable, shipped on blue ice. Upon delivery aliquot and store in fridge, longterm storage at -20°C.

Tested applications

ELISA, WB, IHC, FFPE, IHC